Hey Daniel, @Mason14,
Have either of you come across this specific m6a x cardiovascular failure study?
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263194/
Mason, I know you’ve worked through and posted a lot on the contrary primary mechanism of FTO inhib x chemo cardio toxic and the secondary cardioprotective mechanism of bisantrene (prefacing M1M), so this article’s commentary on how increased FTO/changes in other m6a agents helps cardiac health markers (i.e improved Ca2+ homeostasis) might be of interest/relevance.
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-139
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |